edasalonexent
Selected indexed studies
- Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial. (Neuromuscul Disord, 2021) [PMID:33678513]
- Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy. (J Neuromuscul Dis, 2019) [PMID:30452422]
- A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial. (J Neuromuscul Dis, 2021) [PMID:34120912]
_Worker-drafted node — pending editorial review._
Connections
edasalonexent is a side effect of
Sources
- Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial. (2021) pubmed
- Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy. (2019) pubmed
- A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial. (2021) pubmed
- Assessing the ability of boys with Duchenne muscular dystrophy age 4-7 years to swallow softgel capsules: Clinical trial experience with edasalonexent. (2022) pubmed
- A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. (2017) pubmed
- Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle. (2016) pubmed
- Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis. (2022) pubmed
- Quebec Spinal Muscular Atrophy Newborn Screening Program: The First Year Experience. (2025) pubmed
- Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry. (2019) pubmed